[6-K] JIN MEDICAL INTERNATIONAL LTD. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Jin Medical International Ltd. (NASDAQ: ZJYL) filed a Form 6-K announcing the appointment of Dr. James Jiayuan Tong, age 51, as an Independent Director. Effective 20 June 2025, Dr. Tong becomes Chair of the Nominating & Corporate Governance Committee and joins the Audit and Compensation Committees, thereby increasing the proportion of independent oversight on all three key board panels.

Dr. Tong brings more than 20 years of cross-border experience in finance, investment banking, healthcare and academic research. Recent roles include founder of ThorBay Holdings (2022-present) and Venture Partner at Korea Investment Partners (2019-2022) with a focus on oncology, AR/VR, AI healthcare, medical devices and pre-IPO strategy. He has previously served as CFO and venture partner in both public and private companies, and has managed SEC compliance and M&A processes—skills directly relevant to committee responsibilities. Dr. Tong holds an M.D. from Peking University Health Science Center (1996) and a Ph.D. in Neuroscience from Stony Brook University (2001). There are no family relationships or related-party transactions requiring disclosure under Regulation S-K Item 404. The filing is expressly not incorporated by reference into other SEC filings.

The addition of an experienced, fully independent director with deep financial and healthcare expertise should strengthen Jin Medical’s governance framework and may enhance investor confidence; however, the filing contains no financial data or immediate operational changes.

Positive

• Strengthened board independence by adding a qualified, non-affiliated director to all key committees.
• Deep finance and healthcare expertise aligns with company’s sector focus and may enhance strategic oversight.
• No related-party concerns disclosed, reducing potential governance risk.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR – Adds independent director, marginally improves governance; limited near-term financial impact.

The appointment of Dr. Tong slightly upgrades board independence and committee expertise, aligning with best-practice governance standards expected of U.S.-listed issuers. His mix of venture financing, SEC familiarity and healthcare knowledge is well-matched to Jin Medical’s profile and should aid audit quality and strategic decision-making. That said, the change is routine and does not alter capital structure, revenue outlook or risk profile. Shareholder impact is therefore modest and unlikely to drive valuation in the short term.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Commission File Number: 001-41661

 

Jin Medical International Ltd.

(Exact name of registrant as specified in its charter)

 

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People’s Republic of China

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

Appointment of Independent Director

  

Jin Medical International Ltd. (Nasdaq: ZJYL) (the “Company”) has appointed Dr. James Jiayuan Tong (“Dr. Tong”) to serve as Independent Director and Chairperson of the Nominating and Corporate Governance Committee of the Company, and to serve on the Company’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. The Company’s board of directors (the “Board”) approved Dr. Tong’s appointment on June 20, 2025. Dr. Tong, age 51, is an experienced executive with over twenty years of experience and a diverse background spanning finance, investment, healthcare and academic research. Dr. Tong has held leadership roles across the U.S. and Asia, combining scientific expertise with business acumen. From March 2022 to the date of this report, Dr. Tong has been leading the strategic developments of ThorBay Holdings as its founder, advising on alternative investments, pre-IPO strategy, healthcare ventures, modernized farming assets development, automation and operation. From September 2019 to March 2022, Dr. Tong served as a Venture Partner and Director at Korea Investment Partners, focusing on venture investments and specializing in oncology, healthcare AR/VR 3D and AI solutions, neurological diseases, medical devices and healthcare services. Earlier in his career, Dr. Tong held multiple executive positions as a venture partner and chief financial officer in public and private companies. He has also worked in investment banking and hospital management. Dr. Tong is experienced in overseeing financial operations, SEC compliance, and cross-border mergers and acquisitions. Dr. Tong owns two patents, has received multiple academic awards, has first-authored a series of academic publications and has lectured at multiple corporate and business-themed events. Dr. Tong earned his M.D. from Peking University Health Science Center in 1996 and his Ph.D. in Neuroscience from Cold Spring Harbor Laboratory of Stony Brook University in 2001.

 

There are no family relationships between Dr. Tong and any director or executive officer of the Company. There are no related party transactions between the Company and Dr. Tong disclosable under Item 404 of Regulation S-K of the Securities Act of 1933.

  

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	Jin Medical International Ltd.
 	 	 
Date: June 24, 2025	By:	/s/ Erqi Wang
 	 	Erqi Wang
 	 	Chief Executive Officer

  

 

2

 

FAQ

Who was appointed as an independent director at Jin Medical International (ZJYL)?

Dr. James Jiayuan Tong was appointed on 20 June 2025.

Which board committees will Dr. Tong join at ZJYL?

He will chair the Nominating & Corporate Governance Committee and serve on the Audit and Compensation Committees.

When did the board approve Dr. Tong’s appointment?

The Board approved the appointment on June 20, 2025.

Are there any related-party transactions between Dr. Tong and Jin Medical?

No. The filing states no related-party transactions under Regulation S-K Item 404.

What is Dr. Tong’s professional background?

Over 20 years in finance, venture investing, healthcare and academia; founder of ThorBay Holdings and former Venture Partner at Korea Investment Partners.

What SEC form did Jin Medical file for this disclosure?

The company filed a Form 6-K as a foreign private issuer.